Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease

Secondary hyperparathyroidism is an early complication of chronic kidney disease, with increasing severity as the glomerular filtration rate decreases and characterized by a progressive increase in parathyroid hormone and growth of the parathyroid glands. It is generally accepted that a deficiency i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lilit V. Egshatyan, Natalya G. Mokrisheva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2018
Materias:	parathyroid glands secondary hyperparathyroidism diabetes mellitus paricalcitol vitamin d receptor activators vitamin d chronic kidney disease Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/e32c7299051d4efba0c77290158f9220
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e32c7299051d4efba0c77290158f9220
record_format	dspace
spelling	oai:doaj.org-article:e32c7299051d4efba0c77290158f92202021-11-14T09:00:21ZSecondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease2072-03512072-037810.14341/DM9458https://doaj.org/article/e32c7299051d4efba0c77290158f92202018-05-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/9458https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Secondary hyperparathyroidism is an early complication of chronic kidney disease, with increasing severity as the glomerular filtration rate decreases and characterized by a progressive increase in parathyroid hormone and growth of the parathyroid glands. It is generally accepted that a deficiency in active form of vitamin D or calcitriol levels seems to play a relevant role in its development and progression of secondary hyperparathyroidism. A reduction in plasma calcitriol levels occurs early in renal disease. Major renal guidelines recommend use of vitamin D for secondary hyperparathyroidism in chronic kidney disease. In the treatment vitamin D receptor activation inhibit glandular hyperplasia; reduce parathyroid hormone levels impact on bone turnover and mineral density. Treatment with calcitriol can occasionally result in hypercalcemia and hyperphosphatemia in renal patients due promotes intestinal calcium and phosphorus absorption. This limits its suitability for the treatment. But next generation vitamin-D analogs such as paricalcitol have lower intestinal absorption of calcium, phosphorous and significantly lowers renin levels, albuminuria and blood pressure. In this article, we present the case of a Caucasian male with type 2 diabetes and secondary hyperparathyroidism in stages 3–4 chronic kidney disease. Our case study shows that in treating for secondary hyperparathyroidisms selective vitamin D receptor activation with paricalcitol reduction of levels parathyroid hormone, albuminuria, offering low chance hypercalcemia, hyperphosphatemia and other side effects.Lilit V. EgshatyanNatalya G. MokrishevaEndocrinology Research Centrearticleparathyroid glandssecondary hyperparathyroidismdiabetes mellitusparicalcitolvitamin d receptor activatorsvitamin dchronic kidney diseaseNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 21, Iss 2, Pp 128-134 (2018)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	parathyroid glands secondary hyperparathyroidism diabetes mellitus paricalcitol vitamin d receptor activators vitamin d chronic kidney disease Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	parathyroid glands secondary hyperparathyroidism diabetes mellitus paricalcitol vitamin d receptor activators vitamin d chronic kidney disease Nutritional diseases. Deficiency diseases RC620-627 Lilit V. Egshatyan Natalya G. Mokrisheva Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
description	Secondary hyperparathyroidism is an early complication of chronic kidney disease, with increasing severity as the glomerular filtration rate decreases and characterized by a progressive increase in parathyroid hormone and growth of the parathyroid glands. It is generally accepted that a deficiency in active form of vitamin D or calcitriol levels seems to play a relevant role in its development and progression of secondary hyperparathyroidism. A reduction in plasma calcitriol levels occurs early in renal disease. Major renal guidelines recommend use of vitamin D for secondary hyperparathyroidism in chronic kidney disease. In the treatment vitamin D receptor activation inhibit glandular hyperplasia; reduce parathyroid hormone levels impact on bone turnover and mineral density. Treatment with calcitriol can occasionally result in hypercalcemia and hyperphosphatemia in renal patients due promotes intestinal calcium and phosphorus absorption. This limits its suitability for the treatment. But next generation vitamin-D analogs such as paricalcitol have lower intestinal absorption of calcium, phosphorous and significantly lowers renin levels, albuminuria and blood pressure. In this article, we present the case of a Caucasian male with type 2 diabetes and secondary hyperparathyroidism in stages 3–4 chronic kidney disease. Our case study shows that in treating for secondary hyperparathyroidisms selective vitamin D receptor activation with paricalcitol reduction of levels parathyroid hormone, albuminuria, offering low chance hypercalcemia, hyperphosphatemia and other side effects.
format	article
author	Lilit V. Egshatyan Natalya G. Mokrisheva
author_facet	Lilit V. Egshatyan Natalya G. Mokrisheva
author_sort	Lilit V. Egshatyan
title	Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
title_short	Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
title_full	Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
title_fullStr	Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
title_full_unstemmed	Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
title_sort	secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease
publisher	Endocrinology Research Centre
publishDate	2018
url	https://doaj.org/article/e32c7299051d4efba0c77290158f9220
work_keys_str_mv	AT lilitvegshatyan secondaryhyperparathyroidisminpatientwithtype2diabetesandstages34chronickidneydisease AT natalyagmokrisheva secondaryhyperparathyroidisminpatientwithtype2diabetesandstages34chronickidneydisease
_version_	1718429560768299008

Secondary hyperparathyroidism in patient with type 2 diabetes and stages 3–4 chronic kidney disease

Ejemplares similares